<p>Clinical studies of Ezetimibe (administered alone or with an HMG-CoA reductase<br />
inhibitor) demonstrated that Ezetimibe was generally well tolerated. The overall<br />
incidence of adverse events reported with Ezetimibe was similar to that reported with<br />
placebo, and the discontinuation rate due to adverse events was also similar for Ezetimibe<br />
and placebo.</p>